IBAB Ion Beam Applications SA

IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH

IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH

Dosimetry portfolio strengthened with Medical Imaging QA and AI validation 

Louvain-la-Neuve, Belgium, 03 November 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a world-leading provider of quality assurance (QA) solutions, today announces the acquisition of PhantomX GmbH, expanding IBA’s portfolio in healthcare diagnostics and therapeutic systems enabling artificial intelligence (AI) quality assurance.

Founded in 2018 by Dr. Paul Jahnke and Dr. Felix Schwarz, with support from Charité University Hospital in Berlin, PhantomX is a recognized leader in the development of realistic anthropomorphic phantoms. The company’s proprietary advanced quality assurance technologies are used globally for validating diagnostic and therapeutic imaging systems, as well as medical education and training. PhantomX is at the forefront of quality assurance for AI applications in medical imaging and provides tools for AI-enhanced clinical solutions. 

“PhantomX’s expertise in AI validation perfectly complements IBA’s portfolio of Clinical Workflow Solutions in Radiation Therapy and Medical Imaging,” said Jean-Marc Bothy, President of IBA Dosimetry. “Together, we will accelerate innovation in our Medical Imaging Business Line with simulation and AI-driven technologies, delivering greater value to clinicians and patients worldwide.”

Dr. Paul Jahnke, one of the Founders of PhantomX, added: “This merger empowers us to bring our technology to new markets and contribute to the future of intelligent, safe, and effective medical solutions.”

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: .



For further information, please contact:

IBA Investor Relations

Thomas Pevenage

 890

IBA Corporate Communication

Olivier Lechien

 890

Attachment



EN
03/11/2025

Underlying

IBABIon Beam Applications SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE
Free
IBAB Ion Beam Applic...

IBA – ACQUISITION OF OWN SHARES

IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, March 30th, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until September 30th, 2026 (included), effective as from February 3rd, 2026...

March 30, 2026 1 EN
 PRESS RELEASE
Free
IBAB Ion Beam Applic...

IBA – ACQUISITION D’ACTIONS PROPRES

IBA – ACQUISITION D’ACTIONS PROPRES Louvain-la-Neuve, Belgique, 30 mars 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 2 février 2026. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 400.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 30 septembre 2026 et effectif à parti...

March 30, 2026 1 EN
ING Helpdesk
  • ING Helpdesk
SOF SOFINA SA
IBAB Ion Beam Applic... ... (+5)

Benelux Morning Notes

AEGON: merger of Corebridge and Equitable, implications for Transamerica. Flow Traders: Equity strong as crypto fades. IBA: Net debt above, FY26 REBIT guidance on the low side, 2H25 REBIT a bit below. Sofina: Final NAV 2% above preliminary results. Zabka: Peer Dino Polska FY25 results

SOF SOFINA SA
IBAB ION BEAM APPLICATIONS SA
FLOW FLOW TRADERS LTD
AGN AEGON N.V.
ZAB ZABKA GROUP
03/27/26 March 27, 2026 1 EN
Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Kristof Samoy
  • Livio Luyten
  • Thomas Couvreur
  • Wim Hoste
EXM EXMAR N.V.
SOF SOFINA SA
IBAB ION BEAM APPLICATIONS SA
ARCAD ARCADIS NV
03/27/26 March 27, 2026 1 EN
Wim Hoste
  • Wim Hoste
IBAB Ion Beam Applic...

IBA FIRST LOOK: FY25 REBIT +58%, FY26 guidance of at least 17% growth

IBA reported solid FY25 results, with revenues up 24% to € 620m (kbcse: € 614m), driven by an accelerated backlog conversion and good order intake. However, gross profit margins still contracted by 150bps to 32.2%, driven by negative mix effects from legacy lower margin PT contracts. Nevertheless, as this was already anticipated, the FY25 REBIT of € 27.4m came in above the guidance of at least € 25m and was in line with our forecast. The 2026 guidance calls for a REBIT of at least € 32m (kbcse: ...

IBAB ION BEAM APPLICATIONS SA
03/27/26 March 27, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch